FDA Clears SPR Therapeutics’ Non-opioid SPRINT endura and extensa Peripheral Nerve Stimulation Systems for Pain ManagementApprovals, FDA/Regulatory, Neurostimulation, Peripheral Nerve Stimulation (PNS) Systems, PhysiciansSPR Therapeutics Inc., a leader in neurostimulation technology for pain, announced that the U.S. Food and Drug Administration cleared the company’s SPRINT endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation Systems. Read more August 16, 2018/by GlobeNewswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 GlobeNewswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png GlobeNewswire2018-08-16 08:30:302018-08-16 08:30:30FDA Clears SPR Therapeutics’ Non-opioid SPRINT endura and extensa Peripheral Nerve Stimulation Systems for Pain Management
